JP Morgan analysts see a potential lifeline for Teva Pharmaceutical (NYSE:TEVA) after upgrading the stock to Overweight and raising the price target to $23. The move follows Teva's announcement of a $700 million cost-cutting program, aimed at offsetting the anticipated revenue drop from gRevlimid while still investing in its pipeline. JP Morgan analysts believe this initiative could help Teva close the gap toward its 30% operating margin target by 2027. Despite the stock's 20% drop YTD, some analysts are starting to see a path forward, as reflected in the current consensus: three Buy, five Outperform, and three Hold ratings.

Warning! GuruFocus has detected 2 Warning Signs with TEVA.Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock?

Teva's strategic pivot comes at a time when investors are scrutinizing its ability to manage financial pressures while stabilizing margins. JP Morgan's analysts noted that Teva's margin trajectory in 2026-2027 was a key concern, particularly given the dual challenges of declining gRevlimid sales and necessary R&D investments. The latest rating breakdown, however, shows a cautious shift the number of Hold ratings has remained consistent, suggesting some skepticism about Teva's ability to execute its cost-cutting plan effectively.

For investors, the question now is whether Teva can deliver on its margin targets without sacrificing long-term growth. With JP Morgan's endorsement and a newly defined cost structure, the market may be reassessing the stock's potential upside. But with multiple Hold ratings still in place, Teva's ability to navigate the next few quarters could be pivotal in swaying investor sentiment and moving the stock closer to the $23 target.

This article first appeared on GuruFocus.

View Comments